CoChat

Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

Open access
Ekström, Nils, Schiöler, Linus, Svensson, Ann-Marie, Eeg-Olofsson, Katarina, Miao Jonasson, Junmei, Zethelius, Björn, Cederholm, Jan, Eliasson, Björn, Gudbjörnsdottir, Soffia · 2012 · BMJ Open

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Objective: To evaluate the effectiveness and safety of metformin use in clinical practice in a large sample of pharmacologically treated patients with type 2 diabetes and different levels of renal function. Design: Observational study between July 2004 and December 2010, mean follow-up 3.9 years. Setting: Hospital outpatient clinics and primary care in Sweden. Participants: 51 675 men and women with type 2 diabetes, registered in the Swedish National Diabetes Register, and on continuous glucose-lowering treatment with oral hypoglycaemic agents (OHAs) or insulin. Main outcome measures: Risks of cardiovascular disease (CVD), all-cause mortality and acidosis/serious infection, associated with each treatment regimens, were analysed in all patients and in subgroups with different estimated glomerular filtration rate (eGFR) intervals. Covariance adjustment and propensity scores were used to adjust for several baseline risk factors and characteristics at Cox regression. Results: Compared with metformin in monotherapy, HRs for fatal/non-fatal CVD and all-cause mortality with all other OHAs combined (approximately 80% sulphonylureas) in monotherapy were 1.02 (95% CI 0.93 to 1.12) and 1.13 (1.01 to 1.27), while 1.18 (1.07 to 1.29) and 1.34 (1.19 to 1.50) with insulin in monotherapy, adjusting using propensity scores. Metformin, compared with any other treatment, showed reduced risks of acidosis/serious infection (adjusted HR 0.85, 95% CI 0.74 to 0.97) and all-cause mortality (HR 0.87, 95% CI 0.77 to 0.99), in patients with eGFR 45–60 ml/min/1.73 m 2 , and no increased risks of all-cause mortality, acidosis/serious infection or CVD were found in patients with eGFR 30–45 ml/min/1.73 m 2 . Conclusions: Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all-cause mortality compared with other OHA, in these 51 675 patients followed for 4 years. Patients with renal impairment showed no increased risk of CVD, all-cause mortality or acidosis/serious infection. In clinical practice, the benefits of metformin use clearly outbalance the risk of severe side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2012-001076

Cites

39 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Time (months) to event of all-cause mortality (A), any cardiovascular disease (CVD) (B) and any acidosis/serious infection (C) in each treatment group, unadjusted. OHA, oral hypoglycaemic agent.
Figure 1 Time (months) to event of all-cause mortality (A), any cardiovascular disease (CVD) (B) and any acidosis/serious infection (C) in each treatment group, unadjusted. OHA, oral hypoglycaemic agent.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Metadata

Authors
Ekström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S.
Affiliations
  • University of Gothenburg (SE)
  • Region Västra Götaland (SE)
  • Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Centre of Registers in Region Västra Götaland, Gothenburg, Sweden
  • Uppsala University (SE)
Corresponding author
Ekström, Nils
Venue
BMJ Open
Publisher
BMJ
Published
2012
Volume
2
Issue
4
Pages
e001076
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2167639134
Cited by
221
References
39
Citations by year
2026: 6 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 19 · 2018: 13 · 2017: 26 · 2016: 18 · 2015: 18 · 2014: 29 · 2013: 13
FWCI
15.40
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Sveriges Kommuner och Landsting
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
metformin, type 2 diabetes, renal function, estimated glomerular filtration rate, cardiovascular disease, all-cause mortality, lactic acidosis, serious infections, sulfonylureas, insulin monotherapy, oral antidiabetic drugs, drug safety, treatment effectiveness, Swedish National Diabetes Register, propensity score adjustment, real-world clinical practice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.